The agency sent a warning letter to Kalchem International for CGMP violations found at the company’s Lindsay, OK, facility.
FDA sent a warning letter, dated Aug. 27, 2020, to Kalchem International after an inspection of the company’s Lindsay, OK, facility found violations of current good manufacturing practices (CGMPs). The inspection was conducted from February 10–21, 2020.
Specifically, according to FDA, the company shipped drug product before receiving the certificate of analysis with assay results from its contract laboratory and batch records were reviewed and approved after the batch was released. The agency requested in the warning letter that the company provide FDA with a list of chemical and microbial specifications used to analyze product batches, an assessment of the company’s laboratory practices and procedures, and a remediation plan to ensure the company’s quality unit (QU) properly functions.
The warning letter also stated that the company’s QU failed to adequately ensure that API met CGMP requirements. Records were not maintained and reviewed for each API that was relabeled, according to FDA. Re-packaging batch records were also not adequately reviewed before release. “For example, one lot of Lidocaine HCL was re-packaged with an incorrect lot number and shipped. Your QU reviewed the Chemical Repackaging record six days after the product had been shipped. The error was not detected until the FDA investigator found it during our inspection,” the letter stated. FDA asked the company to provide a risk assessment of the hazards of inadequate documentation and oversight of relabeled drugs.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.